Genzyme's Buyout Of SangStat: Ripening Treasure In Polyclonals?
Last week's news of a planned $600 million cash buyout of SangStat Medical Corp. by Genzyme Corp. made headlines for its obvious virtues on both sides - but down the road an even bigger boon might be coming for the merged pair. It's a benefit that inspired phrases such as "medical revolution" and "whole new world" from Bill Martin, director of corporate communications for SangStat.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter